An observational case-control study to find relationship between MGMT gene polymorphism and haematological toxicities
Not Applicable
- Conditions
- Health Condition 1: C719- Malignant neoplasm of brain, unspecified
- Registration Number
- CTRI/2022/04/041804
- Lead Sponsor
- Tata Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Age over 18 years at time of diagnosis.
2.Newly diagnosed diffuse glioma (Grade II-IV) being treated or previously treated with Radiotherapy plus concurrent Temozolomide +/- Adjuvant Temozolomide who developed no toxicity or Grade I myelotoxicity
3.Written informed consent.
Exclusion Criteria
1.Recurrent gliomas treated with salvage systemic therapies.
2.Progression found before randomization/after Surgery.
3.Patients with previous history of myelosuppression due to any other cause.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.To determine incidence of MGMT gene polymorphism in patients with GrII and above myelotoxicity (cases) and in patients with GrI or no toxicity (controls) in adult diffuse gliomas <br/ ><br>2.To compare the incidence of presence of MGMT gene polymorphism in patients with GrIII and above toxicity and in patients with grade I or no toxicity. <br/ ><br>3.To elucidate correlation/association/causal relationship between presence of MGMT gene polymorphism and grade III and above myelotoxicity.Timepoint: During RT with Conc TMZ and Adj TMZ
- Secondary Outcome Measures
Name Time Method ot ApplicableTimepoint: Not Applicable